Help us: Donate
Follow us on:
×

Menu

Back

Maximon Launches Longevity Biotech Builder

This company intends to promote healthy lifespan through forming longevity startups.

Maximon logoMaximon logo
 

We kick off the week with some news from Switzerland and introduce the new longevity biotech company builder Maximon.

The enthusiasm for technologies to promote longevity and even increase healthy human lifespan seems to be rising in Switzerland. There are frequently articles in the popular press about the topic and we were even asked to write an article for Schweizer Monat (Swiss Month) in February 2020 called “The ways to longevity“, which took a look at the near-future longevity tech that could change how we age.

We include the official press release below and let it do most of the talking, but in a nutshell, Maximon is a Switzerland-based biotech incubator that aims to identify and develop promising biotech companies that focus on creating therapies that target the aging processes and thus increase healthy longevity through the delaying, prevention, or even reversal of age-related diseases.

There are now a number of longevity company builders around the world, all of which approach things in a slightly different way. The arrival of Maximon is most welcome and they appear to be taking a more hands-on approach to building the actual companies from the ground up.

The more companies focused on developing technologies and therapies to support healthy longevity, the better; quite simply, the more rejuvenation startups there are, the greater the chances that one of them will succeed in the near future and show the world that human aging is not a one-way street and that we may have a choice regarding how we age in the next few decades.

Maximon launches the world’s first longevity company builder

Zug/Switzerland, March 8th, 2021 – Maximon is the new company builder based in Switzerland with the aim to extend the health-span and to allow humans to reach a fit, healthy and happy longevity.

Maximon will start several companies per year and provide a comprehensive set of resources that empowers founders to focus on and create superior services and products and execute at speed on a global scale. The resulting company cluster is highly synergetic and allows Maximon to impact the longevity sector from multiple angles simultaneously. Maximon plans to allocate CHF 50million+ over the next 4 years and to raise a larger longevity focused fund thereafter.

“Longevity will be one of the largest, if not the largest, investment opportunities in the decades to come. At Maximon, we want to monetize this huge business opportunity by empowering entrepreneurs to build impactful, science-based and scalable companies that investigate and perpetuate healthy aging and rejuvenation solutions”, says Founding Partner Dr. Tobias Reichmuth. “The recent progress in science relating to life and health extension is very impressive and creates unique and massive business opportunities”, adds the Founding Partner Marc P. Bernegger.

The founding team is complemented by serial entrepreneur and investor Jörg Rieker, venture building expert Caroline Faisst, and three additional team-members.

Maximon is supported by a scientific advisory board consisting of Prof. Dr. Collin Ewald from ETH Zurich and Prof. Dr. Evelyne Yeudit Bischof, MD, MPH from Shanghai University of Medicine and Health Sciences and Human Longevity Inc., by industry advisors like Adrian Locher (Co-Founder of DeinDeal and Merantix) and Alexander Thiel (Partner and Lead Consumer Goods Practice at McKinsey & Company).

Dr. Tobias Reichmuth and Marc P. Bernegger are also the initiators of the “Longevity Investors Conference”, which targets the global investor community.

About Maximon

Maximon is a longevity company builder based in Switzerland with the mission to become the leading player in the field of longevity and healthy lifespan by empowering entrepreneurs to build impactful, science-based and scalable companies, which provide healthy aging and rejuvenation solutions.More information about Maximon can be found on www.maximon.com

About Longevity

Longevity is the science of anti-aging research and rejuvenation and has experienced an unprecedented advance over recent years, particularly with the discovery that the rate of aging is controlled, at least to some extent, by genetic pathways and biochemical processes. Longevity identifies both lifestyle and pharmaceutical targets to improve the human health-span (i.e. the time we can live without any negative impact from aging).

Contact

Maximon Ltd.

Bahnhofplatz

CH-6300 Zug

Switzerland

Email: [email protected]

CategoryNews
About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.